Your clinicians are already doing the clinical work — treating heart failure, managing CKD, adjusting diabetes regimens. The gap is between what was done and what the documentation captures and defends. Over one month of visits we found 69 reviewable HCC findings (a further 18 low-confidence hits were suppressed by our confidence model and are not counted anywhere in this report), a visit-level coding pattern that under-codes 29% of billed visits, and 68 documented conditions that would not survive a RADV audit as written. Every finding below is tied to verbatim evidence from your own notes, and every number traces to a footnoted method in the appendix.
Framing note: this lookback sizes prospective opportunity — what the same clinical work would capture going forward with pre-visit documentation support. It is not a proposal to re-bill prior claims.
The CDI engine scanned each note's medications, labs, vitals, and narrative against 115 CMS-HCC V28 condition profiles, then scored every candidate through the same confidence model that gates our production physician queries. Findings the model wasn't confident in were suppressed, not shown. What remains is grouped by confidence lane:
| HCC | Condition | Finding type | Lane | Patients | Coeff (CNA)2 | Annualized $1 |
|---|---|---|---|---|---|---|
| HCC 155 | Major depressive disorder, moderate — PHQ-9 & SSRI present, dx absent | Suspect | High | 6 | 0.299 | $20,369 |
| HCC 226 | Congestive heart failure, chronic — carried in PMH, dropped this year | Dropped | High | 5 | 0.306 | $17,372 |
| HCC 37 | Diabetes with chronic complications — CKD/neuropathy evidence, coded unspecified | Suspect | High | 9 | 0.166 | $16,963 |
| HCC 280 | COPD — tiotropium + spirometry on file, not documented this period | Dropped | High | 4 | 0.319 | $14,488 |
| HCC 48 | Morbid obesity — BMI 40+ in vitals, never carried to assessment | Suspect | Review | 5 | 0.186 | $10,559 |
| HCC 238 | Atrial fibrillation — on apixaban, rhythm dx absent this year | Dropped | High | 3 | 0.299 | $10,185 |
| HCC 327 | CKD stage 3b — eGFR 30–44 ×2 in window, unstaged in notes | Suspect | Review | 6 | 0.127 | $8,652 |
| HCC 93 | Rheumatoid arthritis — on methotrexate, dx not restated | Dropped | High | 2 | 0.317 | $7,198 |
| …and 29 more findings across 12 HCC categories | — | — | $44,428 | |||
| Total reviewable findings (both lanes) | 69 | +13.23 RAF | $150,214 | |||
Headline uses the high-confidence lane only ($101,278). Review-lane candidates ($48,936) require specialist judgment and are reported separately on purpose — we don't inflate the number we'd be measured against.
Heart failure was documented and coded in 2025 and is being actively treated in this window — but no HF diagnosis appears in any 2026 note. Under CMS-HCC, RAF resets every January 1: untouched, this patient's heart failure contributes $0 to 2027 risk-adjusted revenue.
In production, this finding becomes a pre-visit query to the physician, rendered from our V28 template catalog and passed through a 7-point AHIMA/ACDIS compliance gate before it can be sent. This is the actual rendered output — note it contains no codes, no scores, and no financial language:
This patient's record is being reviewed ahead of their upcoming visit as part of routine pre-visit documentation review. The following clinical indicators were noted in the record:
Based on your clinical judgment, can the status of this patient's heart failure be clarified in the documentation for the upcoming encounter?
Clinical criteria reference available on request. This query is not a directive to add a diagnosis; document only what is clinically supported.
Each note was independently leveled by the THS coding engine (2021 AMA MDM rules, catalog-based, evidence-linked per element) and compared against the code your team billed4. 602 of 624 charts had a billed E/M code available for comparison.
| Code | Billed | Engine | CMS ref5 |
|---|---|---|---|
| 99202 | 6% | 3% | 4% |
| 99203 | 48% | 35% | 36% |
| 99204 | 38% | 48% | 47% |
| 99205 | 8% | 14% | 13% |
| Shift (documentation-supported) | Visits | Annualized4,7 |
|---|---|---|
| 99213 → 99214 | 118 | $54,570 |
| 99214 → 99215 | 33 | $16,868 |
| 99203/04 → higher (new pts) | 14 | $9,529 |
| 99212 → 99213 | 8 | $3,408 |
| Over-coded — corrected down | 65 | −$30,693 |
| Net supported E/M lift | $53,682/yr |
| Provider | Visits | Billed avg level | Engine avg level | Under-coded | Over-coded |
|---|---|---|---|---|---|
| Provider A | 168 | 3.31 | 3.52 | 31% | 6% |
| Provider B | 147 | 3.38 | 3.49 | 26% | 9% |
| Provider C | 152 | 3.22 | 3.55 | 35% | 4% |
| Provider D | 135 | 3.45 | 3.51 | 19% | 14% |
Provider C leaves the most on the table; Provider D carries the most audit exposure. Same tool fixes both — that's the bidirectional point.
Capturing an HCC is half the job; defending it is the other half. CMS RADV audits test whether each documented condition shows Monitoring, Evaluation, Assessment, or Treatment linked to that condition in the encounter. We assessed all 391 HCC-mapped conditions you documented this window with the THS MEAT engine (per-diagnosis, assertion-gated — a med-list mention alone does not count).
| Condition | HCC | Patients | MEAT present | What the note shows | $ exposed1,2 |
|---|---|---|---|---|---|
| COPD | 280 | 5 | MEAT | "Tiotropium — refill ×90d" on med list; condition never assessed or linked to a plan | $18,110 |
| Major depression | 155 | 4 | MEAT | PHQ-9 of 14 recorded; no assessment statement, no treatment plan this year | $13,579 |
| Morbid obesity | 48 | 6 | MEAT | BMI 41.2 auto-populated in vitals; diet program referenced once; dx never restated | $12,671 |
| Atrial fibrillation | 238 | 3 | MEAT | On apixaban with dx coded — but rhythm status/monitoring never documented in window | $10,185 |
| CKD stage 3b | 327 | 7 | MEAT | Coded from problem list; eGFR 44 sits in labs uncommented — no monitoring statement | $10,094 |
| …and 43 more condition instances (lower-coefficient HCCs) | $25,285 | ||||
| Total revenue at RADV risk as currently written | $89,924 | ||||
In production, every one of these becomes a specific, one-line strengthening prompt at the point of care ("link the eGFR to your CKD assessment"), not a retrospective cleanup project. That's how the 82.6% moves toward 100% without adding documentation time.
Your window volume annualizes to ~7,594 claims/yr7 against stated collections of $1.48M. Your current arrangement (~6% of collections, bundled) costs $88,800/yr. THS runs on a transparent stack — Stedi clearinghouse at ~$0.50/claim round-trip plus AI coding with near-zero marginal cost — so we can price below incumbents and show you the math:
| Model | Structure | Annual cost | Savings vs. current | Best for |
|---|---|---|---|---|
| C1 — Capped % lead offer | 3.5% of net collections, capped — same mental model as today, roughly half the rate | $51,800 | $37,000 | Lowest-friction switch |
| C2 — Transparent stack | $300/provider/mo + clearinghouse at cost +15% | $18,767 | $70,033 | Practices done with the % tax |
| C3 — Per-claim | $3.50 per processed claim, all-in | $26,579 | $62,221 | High-volume, low-complexity |
Everything above was found in your charts by the same engines you'd be buying. The recommended path starts with the CDI platform (where this report found $182,610/yr) and adds coding and billing only when each step has proven itself.
You pay 22% of defensible incremental RAF revenue — validated, MEAT-supported, physician-signed lift only. No lift, no fee. Never priced on code volume.
| High-confidence missed HCC revenue (Section 1) | $101,278/yr |
| × validated-and-signed rate (conservative assumption)3 | × 70% |
| Expected captured lift, year one | $70,895 |
| THS performance fee (22%) | −$15,597 |
| Your practice keeps | $55,298/yr |
Plus the defensive value: the $89,924 at RADV risk (Section 3) gets MEAT-hardened as part of the same workflow — at no per-query charge. Alternate structures if you prefer flat pricing: $3.00 per attributed member/month ($22,320/yr on your 620-member panel), or $55 per accepted, signed HCC.
| Step | What it adds | Price | When | |
|---|---|---|---|---|
| Start | 1 · CDI / HCC platform | Pre-visit gap detection + compliant physician queries + MEAT hardening (Sections 1 & 3) | 22% of validated lift | Day 1 — runs on your athenahealth via Marketplace/FHIR, no EHR change |
| 2 · Coding services | Every encounter coded: ICD-10 + CPT + E/M + CCI, with line-level rationale (Section 2) | $2.25/encounter (~$17,087/yr) · +17% audit-defensible QA tier | When CDI has proven accuracy on your charts | |
| 3 · Billing / RCM | Full claim lifecycle on the transparent Stedi stack (Section 4) | 3.5% capped → transparent stack at renewal | When the cost delta is self-evident |
Next step: a 30-minute walkthrough of this report with your physicians — we bring the per-patient evidence behind every number in Section 1, on screen, in the same dashboard your team would use.
638 charts received → 14 excluded for scan quality (listed separately for your records) → 624 analyzed. Each chart ran through the production THS engines — the identical code paths a subscribing practice runs: outpatient coding (11-phase, 2021 AMA MDM catalog engine; internally gated at 82% exact / 100% ±1 E/M agreement on validation corpora), outpatient CDI (9-phase CMS-HCC V28 scan, 115 condition profiles, confidence-calibrated), MEAT engine (per-diagnosis, assertion-gated), and the V28 query renderer (every sample query in this report passed the same 7-point AHIMA/ACDIS compliance gate used in production). 22 charts lacked a billed E/M code and are excluded from Section 2 accuracy denominators only. 18 low-confidence HCC hits were suppressed by the confidence model and excluded from all dollar figures.
This lookback is opportunity sizing for prospective, going-forward capture. It is not an offer to re-bill, re-code, or amend previously submitted claims, and no prior-period correction is proposed here; any such review would be a separate, bidirectional exercise (adding supported and removing unsupported codes) conducted with your compliance counsel. THS pricing is never based on code volume — performance fees apply only to defensible, MEAT-validated, physician-signed documentation lift. Physicians never see financial figures inside queries; all sample queries herein contain no codes, risk scores, or dollar amounts, consistent with AHIMA/ACDIS 2022 compliant-query practice. Patient references are de-identified (initials, age/sex, date of service). Chart data was processed under BAA with document parsing performed locally; charts and derived data are purged per the data-handling agreement (default 90 days). This report contains estimates based on documentation review; actual results depend on payer mix, enrollment, and clinical documentation at the point of care.